These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 9034152

  • 1. Mapping the active site of CD59.
    Yu J, Abagyan R, Dong S, Gilbert A, Nussenzweig V, Tomlinson S.
    J Exp Med; 1997 Feb 17; 185(4):745-53. PubMed ID: 9034152
    [Abstract] [Full Text] [Related]

  • 2. Activity after site-directed mutagenesis of CD59 on complement-mediated cytolysis.
    Zhu X, Gao M, Ren S, Wang Q, Lin C.
    Cell Mol Immunol; 2008 Apr 17; 5(2):141-6. PubMed ID: 18445344
    [Abstract] [Full Text] [Related]

  • 3. Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59.
    Bodian DL, Davis SJ, Morgan BP, Rushmere NK.
    J Exp Med; 1997 Feb 03; 185(3):507-16. PubMed ID: 9053451
    [Abstract] [Full Text] [Related]

  • 4. Mapping the intermedilysin-human CD59 receptor interface reveals a deep correspondence with the binding site on CD59 for complement binding proteins C8alpha and C9.
    Wickham SE, Hotze EM, Farrand AJ, Polekhina G, Nero TL, Tomlinson S, Parker MW, Tweten RK.
    J Biol Chem; 2011 Jun 10; 286(23):20952-62. PubMed ID: 21507937
    [Abstract] [Full Text] [Related]

  • 5. Identification of mutations in rat CD59 that increase the complement regulatory activity.
    Hinchliffe SJ, Morgan BP.
    Biochemistry; 2000 May 16; 39(19):5831-7. PubMed ID: 10801333
    [Abstract] [Full Text] [Related]

  • 6. Contribution of the N-linked carbohydrate of erythrocyte antigen CD59 to its complement-inhibitory activity.
    Ninomiya H, Stewart BH, Rollins SA, Zhao J, Bothwell AL, Sims PJ.
    J Biol Chem; 1992 Apr 25; 267(12):8404-10. PubMed ID: 1373727
    [Abstract] [Full Text] [Related]

  • 7. Insights into the human CD59 complement binding interface toward engineering new therapeutics.
    Huang Y, Smith CA, Song H, Morgan BP, Abagyan R, Tomlinson S.
    J Biol Chem; 2005 Oct 07; 280(40):34073-9. PubMed ID: 16079145
    [Abstract] [Full Text] [Related]

  • 8. Identity of the residues responsible for the species-restricted complement inhibitory function of human CD59.
    Zhao XJ, Zhao J, Zhou Q, Sims PJ.
    J Biol Chem; 1998 Apr 24; 273(17):10665-71. PubMed ID: 9553129
    [Abstract] [Full Text] [Related]

  • 9. Identity of the segment of human complement C8 recognized by complement regulatory protein CD59.
    Lockert DH, Kaufman KM, Chang CP, Hüsler T, Sodetz JM, Sims PJ.
    J Biol Chem; 1995 Aug 25; 270(34):19723-8. PubMed ID: 7544344
    [Abstract] [Full Text] [Related]

  • 10. Identification of the high affinity binding site in the Streptococcus intermedius toxin intermedilysin for its membrane receptor, the human complement regulator CD59.
    Hughes TR, Ross KS, Cowan GJ, Sivasankar B, Harris CL, Mitchell TJ, Morgan BP.
    Mol Immunol; 2009 Apr 25; 46(7):1561-7. PubMed ID: 19200600
    [Abstract] [Full Text] [Related]

  • 11. Defining the CD59-C9 binding interaction.
    Huang Y, Qiao F, Abagyan R, Hazard S, Tomlinson S.
    J Biol Chem; 2006 Sep 15; 281(37):27398-404. PubMed ID: 16844690
    [Abstract] [Full Text] [Related]

  • 12. Molecular basis for a link between complement and the vascular complications of diabetes.
    Acosta J, Hettinga J, Flückiger R, Krumrei N, Goldfine A, Angarita L, Halperin J.
    Proc Natl Acad Sci U S A; 2000 May 09; 97(10):5450-5. PubMed ID: 10805801
    [Abstract] [Full Text] [Related]

  • 13. Elimination of potential sites of glycosylation fails to abrogate complement regulatory function of cell surface CD59.
    Rother RP, Zhao J, Zhou Q, Sims PJ.
    J Biol Chem; 1996 Sep 27; 271(39):23842-5. PubMed ID: 8798614
    [Abstract] [Full Text] [Related]

  • 14. Role of a disulfide-bonded peptide loop within human complement C9 in the species-selectivity of complement inhibitor CD59.
    Husler T, Lockert DH, Sims PJ.
    Biochemistry; 1996 Mar 12; 35(10):3263-9. PubMed ID: 8605162
    [Abstract] [Full Text] [Related]

  • 15. Binding of human and rat CD59 to the terminal complement complexes.
    Lehto T, Morgan BP, Meri S.
    Immunology; 1997 Jan 12; 90(1):121-8. PubMed ID: 9038722
    [Abstract] [Full Text] [Related]

  • 16. High-resolution structures of bacterially expressed soluble human CD59.
    Leath KJ, Johnson S, Roversi P, Hughes TR, Smith RA, Mackenzie L, Morgan BP, Lea SM.
    Acta Crystallogr Sect F Struct Biol Cryst Commun; 2007 Aug 01; 63(Pt 8):648-52. PubMed ID: 17671359
    [Abstract] [Full Text] [Related]

  • 17. Identity of a peptide domain of human C9 that is bound by the cell-surface complement inhibitor, CD59.
    Chang CP, Hüsler T, Zhao J, Wiedmer T, Sims PJ.
    J Biol Chem; 1994 Oct 21; 269(42):26424-30. PubMed ID: 7523406
    [Abstract] [Full Text] [Related]

  • 18. Structural basis for membrane attack complex inhibition by CD59.
    Couves EC, Gardner S, Voisin TB, Bickel JK, Stansfeld PJ, Tate EW, Bubeck D.
    Nat Commun; 2023 Feb 16; 14(1):890. PubMed ID: 36797260
    [Abstract] [Full Text] [Related]

  • 19. A synthetic peptide from complement protein C9 binds to CD59 and enhances lysis of human erythrocytes by C5b-9.
    Tomlinson S, Whitlow MB, Nussenzweig V.
    J Immunol; 1994 Feb 15; 152(4):1927-34. PubMed ID: 7509832
    [Abstract] [Full Text] [Related]

  • 20. Crystal structure of CD59: implications for molecular recognition of the complement proteins C8 and C9 in the membrane-attack complex.
    Huang Y, Fedarovich A, Tomlinson S, Davies C.
    Acta Crystallogr D Biol Crystallogr; 2007 Jun 15; 63(Pt 6):714-21. PubMed ID: 17505110
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.